Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bio-Path Holdings 4710 BELLAIRE BOULEVARD SUITE 210 BELLAIRE TX 77401 USA

www.biopathholdings.com P: 832-742-1357

Description:

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.

Key Statistics

Overview:

Market Capitalization, $K 1,690
Enterprise Value, $K 640
Shares Outstanding, K 679
Annual Sales, $ 0 K
Annual Net Income, $ -16,080 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,370 K
EBIT, $ -15,840 K
EBITDA, $ -15,660 K
60-Month Beta 0.35
% of Insider Shareholders 3.05%
% of Institutional Shareholders 5.74%
Float, K 658
% Float 96.95%
Short Volume Ratio 0.34

Growth:

1-Year Return -90.24%
3-Year Return -97.79%
5-Year Return -99.22%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 88.31%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -6.40 on 11/15/23
Latest Earnings Date 05/10/24
Earnings Per Share ttm -30.20
EPS Growth vs. Prev Qtr 39.62%
EPS Growth vs. Prev Year 34.69%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 02/23/24

BPTH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -375.74%
Return-on-Assets % -248.63%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.09
Book Value/Share 0.71
Interest Coverage -2.79
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar